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Abstract
Background: Low mitochondrial DNA (mtDNA) copy number is a common feature of renal cell carcinoma (RCC), and may
influence tumor development. Results from a recent case-control study suggest that low mtDNA copy number in peripheral
blood may be a marker for increased RCC risk. In an attempt to replicate that finding, we measured mtDNA copy number in
peripheral blood DNA from a U.S. population-based case-control study of RCC.
Methodology/Principal Findings: Relative mtDNA copy number was measured in triplicate by a quantitative real-time PCR
assay using DNA extracted from peripheral whole blood. Cases (n = 603) had significantly lower mtDNA copy number than
controls (n = 603; medians 0.85, 0.91 respectively; P= 0.0001). In multiple logistic regression analyses, the lowest quartile of
mtDNA copy number was associated with a 60% increase in RCC risk relative to the highest quartile (OR= 1.6, 95% CI = 1.1–
2.2; Ptrend = 0.009). This association remained in analyses restricted to cases treated by surgery alone (OR Q1 = 1.4, 95%
CI = 1.0–2.1) and to localized tumors (2.0, 1.3–2.8).
Conclusions/Significance: Our findings from this investigation, to our knowledge the largest of its kind, offer important
confirmatory evidence that low mtDNA copy number is associated with increased RCC risk. Additional research is needed to
assess whether the association is replicable in prospective studies.
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Introduction
Mitochondria, the primary source of energy for eukaryotic cells,
also play an important role in other cellular activities such as
calcium regulation and apoptosis, and are a major target and source
of reactive oxygen species [1]. Each mitochondrion has 2 to 10
copies of a 16.6 kb circular double-stranded mitochondrial DNA
(mtDNA) genome containing 37 genes encoding protein subunits
involved in cellular respiration (N=13), tRNAs (N=22), and
rRNAs (N=2) [1]. Cellular mtDNA content typically ranges from
103 to 104 copies per cell, varying across different cell types [2].
Abnormal cellular mtDNA copy number may be a marker for
mitochondrial dysfunction, a suspected contributor to carcinogen-
esis [2]. As summarized by Chatterjee et al., decreased mtDNA
copy number in tumor cells has been reported for several
malignancies, including renal cell carcinoma (RCC), while
elevated mtDNA copy number has been observed in others [2].
Investigations of two case series of RCC detected reduced mtDNA
content in tumor tissue relative to adjacent normal tissue [3,4].
These findings suggest that mechanisms associated with altered
mtDNA copy number may contribute to RCC development.
In a recent hospital-based case-control study conducted in
Texas, Xing et al. observed that RCC cases (N= 260) were
significantly more likely than controls (N= 281) to have low copy
number of mtDNA in peripheral blood lymphocytes, suggesting
that reduced blood mtDNA content may be a marker of increased
RCC risk [5]. In an attempt to replicate that finding, we
conducted an investigation of peripheral blood mtDNA copy
number in a large population-based case-control study of RCC
among White and African American residents of Chicago and
Detroit [6].
Results
A summary of selected characteristics of cases and controls,
stratified by race, is provided in Table 1. In our study, cases
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(N= 603) had a lower education level than controls (N=603), and
were more likely to be overweight and have a history of
hypertension. As shown in Figure 1, cases had a significantly
lower mtDNA copy number than controls [mean (range) 0.88
(0.10–2.35) and 0.94 (0.30–2.29) respectively; Wilcoxon rank sum
P=0.0001]. Findings from multiple logistic regression analyses of
mtDNA copy number and RCC are summarized in Table 2.
Decreasing mtDNA copy number was associated with increased
RCC risk (per 1 standard deviation decrease: OR=1.2, 95%
CI= 1.0–1.3, P=0.007). The lowest quartile of mtDNA copy
number (Q1) was associated with a 60% increase in RCC risk
relative to the highest quartile (ORQ1= 1.6, 95% CI= 1.1–2.2).
When we further subdivided Q1 using the intra-category median
among controls, the association with RCC was stronger for the
lower subcategory (OR=1.8, 95% CI= 1.2–2.7). The association
with low mtDNA copy number remained when we restricted the
analysis to clear cell RCC (ORQ1= 1.6, 95% CI= 1.1–2.4), cases
treated by surgery with no adjuvant therapy (1.4, 1.0–2.1) and
localized tumors (2.0, 1.3–2.8). Mitochondrial DNA content was
not correlated with time from diagnosis to blood collection
(Spearman correlation=20.06, P=0.11).
Results from analyses stratified by sex and race are shown in
Table 2. The association with low mtDNA copy number was
clearly present among men (ORQ1= 1.8, 95% CI= 1.1–2.7) and
White participants (1.8, 1.2–2.8). Mitochondrial DNA copy
number was not clearly associated with RCC among women
(ORQ1= 1.3, 95% CI= 0.7–2.3) or African American participants
(1.2, 0.7–2.2), although copy number levels below the Q1 intra-
category median were non-significantly associated with risk
(women: OR=1.5, 95% CI= 0.8–3.0; African Americans: 2.1,
1.0–4.4). Tests of interaction between mtDNA copy number and
sex, race, age, body mass index (BMI), smoking status and history
of hypertension were not statistically significant (data not shown).
Discussion
In this case-control study, we observed a statistically significant
association between low peripheral blood mtDNA copy number
and increased risk of RCC. Our finding replicates that of an earlier
hospital-based study that found individuals with mtDNA copy
number below the median among controls to have a 50%
increased risk of RCC, with a dose-response relationship between
lower mtDNA copy number and increasing risk [5]. In our study,
the association with low mtDNA copy number appeared to be
stronger for men than women, and for White than for African
American participants, although tests of interaction were not
statistically significant. Xing et al. did not report any differences in
this association between men and women in their study, which
Table 1. Selected characteristics of cases and controls, by race, in the Kidney Cancer Study, 2002–2007.
White African American
Cases Controls Cases Controls
(N=445) (N=379) (N=158) (N=224)
N (%) N (%) N (%) N (%)
Study center Chicago 65 (15) 43 (11) 39 (25) 41 (18)
Detroit 380 (85) 336 (89) 119 (75) 183 (82)
Age (years) 50–59 165 (37) 128 (34) 70 (44) 94 (42)
60–69 156 (35) 139 (37) 64 (41) 74 (33)
70+ 124 (28) 112 (30) 24 (15) 56 (25)
Sex Male 256 (58) 247 (65) 109 (69) 110 (49)
Female 189 (42) 132 (35) 49 (31) 114 (51)
Education ,12 Years 65 (15) 39 (10) 41 (26) 37 (17)
H.S. graduate 170 (38) 114 (30) 46 (29) 82 (37)
Some college 109 (24) 91 (24) 51 (32) 82 (37)
4+ years college 101 (23) 135 (36) 20 (13) 23 (10)
Body mass ,25 74 (17) 101 (27) 28 (18) 52 (23)
index 252,30 166 (37) 172 (45) 58 (37) 93 (42)
(kg/m2) 302,35 115 (26) 63 (17) 36 (23) 40 (18)
35+ 84 (19) 42 (11) 34 (22) 38 (17)
Don’t know 6 (1) 1 (,1) 2 (1) 1 (,1)
Smoking Never 152 (34) 148 (39) 46 (29) 70 (31)
status Occasional 21 (5) 11 (3) 13 (8) 16 (7)
Former 174 (39) 168 (44) 50 (32) 86 (38)
Current 98 (22) 52 (14) 49 (31) 52 (23)
History of No 176 (40) 218 (58) 34 (22) 90 (40)
hypertension Yes 264 (59) 160 (42) 123 (78) 133 (60)
Don’t know 5 (1) 1 (,1) 1 (1) 1 (,1)
Abbreviation: H.S. = high school.
doi:10.1371/journal.pone.0043149.t001
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consisted entirely of White participants. They did note findings
suggestive of effect modification by smoking, which we did not
observe in our study.
The association with blood mtDNA copy number observed in
these two case-control studies is consistent with evidence that
mtDNA copy number is decreased in RCC cells. Reduced
mtDNA content in RCC tissue relative to adjacent normal tissue
was detected by Meiehofer et al. for 34 of 37 cases and by
Selvanayagram et al. for 8 of 13 cases [3,4]. Selvanayagram et al.
also observed mitochondrial depletion in five of six RCC cell lines
[4]. The findings by Meierhofer et al. were independent of stage,
metastasis, ploidy or proliferative activity, suggesting that the
mechanisms associated with mtDNA depletion are early carcino-
genic events which do not change with tumor progression. There
are several possible mechanisms associated with low mtDNA copy
number that could potentially contribute to RCC development,
including resistance to apoptosis [7,8], up-regulation of nuclear
factor-kappa B signaling [9], and increased production of reactive
oxygen species [10,11]. Further research will be necessary to fully
elucidate the underlying pro-neoplastic mechanisms.
Strengths of our study include its large sample size, the inclusion
of African Americans, and its population-based design. A
limitation intrinsic to our study design, and that of Xing et al.
[5], is the use of blood collected after diagnosis. As a consequence,
we cannot determine whether the association with low peripheral
blood mtDNA copy number reflects an etiologic mechanism or an
effect of disease. Our finding for low mtDNA remained when we
restricted the analysis to cases with localized disease and those
treated by surgery only, and mtDNA copy number was not
associated with time from diagnosis to blood collection. While
these results argue against the presence of bias due to tumor- or
treatment-induced effects, we nonetheless cannot rule out reverse
causation as an explanation for our findings. Prospective studies of
mtDNA copy number and RCC involving pre-diagnostic blood
specimens are needed to resolve this question.
In conclusion, our case-control study offers confirmatory
evidence that low peripheral blood mtDNA copy number is
associated with RCC risk. These findings support a role for
mitochondrial effects in RCC development. More research is
needed to understand the biologic mechanisms underlying this
association, including investigations involving peripheral blood,
tumor and adjacent normal kidney tissue, and to assess whether
the association is replicable in prospective studies.
Materials and Methods
Ethics Statement
Study procedures were approved by Institutional Review
Boards (IRBs) at NCI (Special Studies IRB), Wayne State
Table 2. Association between blood mitochondrial DNA (mtDNA) copy number and renal cell carcinoma risk (overall and stratified
by sex and race) in the Kidney Cancer Study, 2002–2007.
mtDNA Copy Number All Subjects Men Women White African American
NCa/NCo OR
1 (95%CI) NCa/NCo OR (95%CI) NCa/NCo OR (95%CI) NCa/NCo OR (95%CI) NCa/NCo OR (95%CI)
per SD decrease2 603/603 1.2 (1.0–1.3) 365/357 1.2 (1.0–1.4) 238/246 1.2 (1.0–1.4) 445/379 1.3 (1.1–1.5) 158/224 1.1 (0.9–1.3)
Q4 (.1.08) 119/150 1.0 69/82 1.0 50/68 1.0 72/80 1.0 47/70 1.0
Q3 (0.92–1.08) 133/151 1.0 (0.7–1.4) 73/84 1.0 (0.6–1.6) 60/67 1.1 (0.6–1.9) 102/93 1.2 (0.7–1.8) 31/58 0.9 (0.5–1.7)
Q2 (0.76–0.91) 140/151 1.1 (0.7–1.5) 88/97 1.1 (0.7–1.7) 52/54 1.1 (0.6–2.0) 106/107 1.2 (0.7–1.8) 34/44 1.1 (0.6–2.1)
Q1 (,0.76) 211/151 1.6 (1.1–2.2) 135/94 1.8 (1.1–2.7) 76/57 1.3 (0.7–2.3) 165/99 1.8 (1.2–2.8) 46/52 1.2 (0.7–2.2)
0.66–0.763 89/76 1.4 (0.9–2.1) 55/46 1.5 (0.9–2.6) 34/30 1.1 (0.6–2.2) 74/44 1.9 (1.1–3.2) 15/32 0.7 (0.3–1.5)
,0.663 123/75 1.8 (1.2–2.7) 81/48 2.0 (1.2–3.3) 42/27 1.5 (0.8–3.0) 92/55 1.8 (1.1–3.0) 31/20 2.1 (1.0–4.4)
Ptrend = 0.009 Ptrend = 0.01 Ptrend = 0.37 Ptrend = 0.006 Ptrend = 0.47
Abbreviations: mtDNA=mitochondrial DNA; NCa = number of cases; NCo = number of controls; OR =odds ratio; CI = confidence interval; SD = standard deviation;
Q1 = quartile 1; Q2 =quartile 2; Q3 = quartile 3; Q4 =quartile 4.
1Odds ratio computed from unconditional logistic regression models adjusted for study center, age group, sex (except for sex-specific models), race (except for race-
specific models), education level, BMI, smoking status, and history of hypertension.
2Standard deviation = 0.27.
3Quartile 1 split into two subcategories using intra-quartile median (i.e., twelfth-and-a-half percentile) among controls as cutpoint.
doi:10.1371/journal.pone.0043149.t002
Figure 1. Peripheral blood mitochondrial DNA copy number in
renal cell carcinoma cases and controls in The Kidney Cancer
Study, 2002–2007. The box plots describe the median (solid line
across the box), mean (dotted line), inter-quartile range and outliers
(circles outside the ends of whiskers) for each study group. The P-value
is from a comparison of mtDNA copy number distribution between
cases and controls using the Wilcoxon rank sum test.
doi:10.1371/journal.pone.0043149.g001
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University (Medical Pediatric Institutional Review Board, MP2)
and the University of Illinois-Chicago (IRB #1), and written
informed consent was obtained from all subjects.
Study Design
The study design and specimen collection methods have been
previously described [6]. Briefly, the Kidney Cancer Study (KCS)
was conducted between 2002 and 2007 within the metropolitan
areas of Detroit, MI and Chicago, IL. Cases of histologically
confirmed incident RCC were identified in Detroit through the
Metropolitan Detroit Cancer Surveillance System, and in Chicago
through reviews of pathology reports from hospitals located in
Cook County. In both study centers, eligible controls were selected
from the general population and frequency matched to cases on
sex, age (5-year intervals), and race. Participating cases (N= 1,217;
77% of contactable eligible individuals) and controls (N=1,235;
54%) were interviewed to collect information on RCC risk factors
such as anthropometric characteristics, smoking, hypertension and
family history of cancer. Non-fasting blood specimens were also
collected at the time of interview from 952 cases and 920 controls.
Among cases, the median time from RCC diagnosis to blood
specimen collection was ,4 months.
Laboratory Analysis
For this investigation we used DNA samples previously
extracted from whole blood specimens from subjects aged $50
with no family history of kidney cancer (604 cases, 603 controls).
We excluded individuals aged ,50 years or with a family history
of kidney cancer from this investigation (208 cases,217 controls)
because peripheral blood DNA for cases in this group had been
extracted from buffy coat, which has been shown to yield
systematically lower mtDNA copy number compared to whole
blood [12]. We also excluded individuals from whom DNA was
unavailable at the time of investigation (140 cases, 100 controls).
Our use of DNA extracted from whole blood is consistent with the
methods of the initial study by Xing et al [5].
We used a quantitative real-time PCR assay, previously
described [13,14], to measure relative mtDNA copy number,
defined as the ratio of mitochondrial (Mt) gene copy number to
single-copy nuclear gene (S) copy number in study samples
compared to reference DNA. The ratio is proportional to the
mtDNA copy number in each cell. The reference single-copy
nuclear gene used in this study was human hemoglobin b (HBB).
The Mt PCR mix was: ITAQ SYBR Green Supermix with Rox
(Bio-Rad) 16, MtF3212 500 nM, MtR3319 500 nM, EDTA 16.
The S (HBB) PCR mix was: ITAQ SYBR Green Supermix with
Rox (Bio-Rad) 16, hbgF 500 nM, hbgR 500 nM, EDTA 16. All
PCRs were done on a 7900HT Fast Real-Time PCR system
(Applied Biosystems, Foster City, CA, USA). DNA (4 ng) was
loaded in a 10 ml PCR reaction. A high-precision MICROLAB
STARlet Robot (Hamilton Life Science Robotics, Bonaduz AG,
Switzerland) was used for transferring in a 384-well format plate a
volume of 6 ml reaction mix and 4 ml DNA (1 ng/ml). We used
pooled DNA from 20 participants randomly selected from controls
of this same study (500 ng for each sample) to create in every Mt
and S PCR run a fresh six-point standard curve which ranged
from 20 ng to 0.08 ng. The forward and reverse primers for
mtDNA, which are complementary to the sequence of the ND1
gene, were: MtF3212 59CAC CCA AGA ACA GGG TTT GT39,
and MtR3319 59TGG CCA TGG GTA TGT TGT TA39. The
forward and reverse primers for nuclear gene, which are
complementary to human hemoglobin b (HBB) were: hbgF
59GCT TCT GAC ACA ACT GTG TTC ACT AGC39, and
hbgR 59CAC CAA CTT CAT CCA CGT TCA CC39.
All samples were run in triplicate. The average of the three Mt
measurements was divided by the average of the three S
measurements to calculate the Mt/S ratio for each sample. For
quality control purposes, 20 blind duplicate samples were
interspersed among the test samples. The coefficient of variation
for the Mt/S ratio in duplicate samples was 6.3%. The mtDNA
assay failed for one case specimen, leaving 603 cases and 603
controls in the analysis.
Statistical Analysis
We tested for a difference in the distribution of mtDNA copy
number between cases and controls using the Wilcoxon rank sum
test. To investigate the association between mtDNA copy number
and RCC risk, we computed odds ratios (ORs) and 95%
confidence intervals (CIs) using multiple logistic regression with
adjustment for study center, age group, sex, race, education level,
BMI, smoking status, and history of hypertension. mtDNA copy
number was categorized in some analyses, using the quartiles
among controls as cutpoints. We also conducted analyses with the
first quartile split into two subcategories, using the intra-quartile
median among controls as a cutpoint, to investigate associations
across a wider range of mtDNA copy number. Analyses stratifying
on age group, sex, race, smoking status, BMI, and history of
hypertension were conducted, as well as analyses restricted to cases
treated by surgery only, cases with localized disease, and cases of
clear cell histology.
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